In Part 2A (phase II), 42 patients with recurrent, platinum-sensitive ovarian cancer, and germline BRCA1/2 mutations, who were previously treated with two to four lines of chemotherapy, received maintenance rucaparib 600 mg bid [35]. This evidence concerns the gene BRCA1 and ovarian cancer.